Amgen Inc. — Sponsor Intelligence | 81 EU Trials

Filter these 81 trials by condition, phase, country and more.

Open in Search →

81 Registered trials

24 Recruiting

51 Completed trials

26 Countries active

74 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I

Phase I (Other)

Phase III: 42 Phase II: 12 Phase I/II: 4 Phase IV: 2 Phase I: 8 Phase I (Other): 9 Phase I (FiH): 3 Other: 1

Oversight events:

11 serious breaches 29 temporary halts 1 urgent safety measure 6 corrective measures across 16 trials

View oversight register →

100%

51 of 51 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Non-small cell lung cancer 11 Small cell lung cancer extensive stage 7 Obesity 3 Overweight 3 Ductal adenocarcinoma of pancreas 3 Breast cancer 3 Gastric cancer 3 Prostate cancer 3 Ovarian cancer 2 Small cell lung cancer recurrent 2 Migraine 2 Osteogenesis imperfecta 2

Top IMPs

MARIDEBART CAFRAGLUTIDE 6 ROCATINLIMAB 6 TARLATAMAB 6 AMG 193 3 APREMILAST 3 BEMARITUZUMAB 3 AMG 732 2 BLINATUMOMAB 2 ERENUMAB 2 INEBILIZUMAB 2 OLPASIRAN 2 ROMIPLOSTIM 2

All trials

81 total

Phase 3 Study Assessing Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Orbit) Not authorised

2022-501535-16-00 Phase III 9 countries ROCATINLIMAB
OCEAN(a)-PreEvent - Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction to Prevent first major cardiovascular Events Pending

2025-520554-11-00 Phase III 17 countries
A phase 1/2 study of subcutaneous blinatumomab administration in children with R/R and MRD+ B-ALL Pending

2025-521671-31-00 Phase I/II 3 countries BLINATUMOMAB
AMG 436 as monotherapy and combination therapy in participants with Microsatellite Instability-High/Mismatch Repair Deficient Solid Tumors… Recruiting

2025-524056-63-00 Phase I 3 countries
An Open-label Study to evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in children with gMG Recruiting

2025-520993-20-00 Phase II 4 countries INEBILIZUMAB
Open-label, Uncontrolled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Par… Recruiting

2025-520988-41-00 Phase II 4 countries INEBILIZUMAB
Pediatric Safety Follow-up Study of Prior Treatment with Romosozumab for Osteogenesis Imperfecta Recruiting

2023-503293-21-00 Phase III 7 countries ROMOSOZUMAB
AMG 410 Alone and in Combination with other agents in Participants with KRAS Altered Advanced or Metastatic Solid Tumors Recruiting

2025-521707-48-00 Phase I 7 countries
A Phase 2 Study of AMG 193 in Subjects With MTAP-deleted Advanced NSCLC Recruiting

2024-514459-14-00 Phase II 12 countries AMG 193
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited‑Stage Small‑Cell Lung Cancer (DeLLphi-306) Recruiting

2023-506235-15-00 Phase III 12 countries TARLATAMAB
A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis Recruiting

2023-506471-10-00 Phase III 8 countries ETELCALCETIDE
An Open-label, Rollover Study to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye Disease Recruiting

2025-523280-38-00 Phase II 2 countries AMG 732
Phase 1b Study of Tarlatamab + ZL-1310 +/- Anti-PD-L1 in Small Cell Lung Cancer Recruiting

2025-522888-15-00 Phase I (Other) 5 countries
OCEAN(a)-CCTA - Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction -Coronary Computed Tomography Angiography trial Recruiting

2025-521117-88-00 Phase III 6 countries OLPASIRAN
Maridebart Cafraglutide versus Placebo in Adult Participants with Obstructive Sleep Apnea on Positive Airway Pressure Therapy (MARITIME-OSA-… Recruiting

2025-522703-14-00 Phase III 6 countries MARIDEBART CAFRAGLUTIDE
Phase 3 Study of Xaluritamig Plus Abiraterone vs Investigator's Choice in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer Recruiting

2025-520555-89-00 Phase III 9 countries SILTUXIMAB; XALURITAMIG
A Phase 1/2 Study to Assess AMG 732 in Healthy Subjects and Subjects with Thyroid Eye Disease Recruiting

2024-514110-12-00 Phase I (FiH) 6 countries AMG 732
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and … Recruiting

2024-516652-18-00 Phase III 18 countries MARIDEBART CAFRAGLUTIDE
Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in participants With ANCA-associated Vasculitis Recruiting

2023-503184-42-00 Phase IV 7 countries AVACOPAN
A study to find how well Dazodalibep works and how safe it is in participants with Sjôgren`s Syndrome Recruiting

2024-517513-32-00 Phase III 12 countries DAZODALIBEP
Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Subjects With Metastatic Colorectal Ca… Recruiting

2022-502352-31-00 Phase III 18 countries
Subcutaneous Tarlatamab in Subjects with Extensive Stage Small Cell Lung Cancer (DeLLphi-308) Recruiting

2024-511838-12-00 Phase I (Other) 4 countries
Comparison between ABP 234 and Keytruda® (Pembrolizumab) Recruiting

2024-514304-14-00 Phase I 7 countries
Phase 1 Study of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer Recruiting

2023-504361-23-00 Phase I 3 countries

Showing 1–24 of 81 trials

← All sponsors A–Z